The effect of EGFR-related tyrosine kinase activity inhibition on the growth and invasion mechanisms of prostate carcinoma cell lines

International Journal of Biological Markers

Volumn 18, Issue 2, 2003, Pages 139-146

  Ünlü, Ali ^a   Leake, R E ^b  

^a MERSIN UNIVERSITY   (Turkey)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Epidermal growth factor; Epidermal growth factor receptor; Invasion; Plasminogen activator inhibitor; Prostate cancer; Tyrosine kinase; Urokinase plasminogen activator

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; MATRIGEL; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; UROKINASE; ZM 252868; COLLAGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; LAMININ; MESSENGER RNA; PLASMINOGEN ACTIVATOR; PROTEOGLYCAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INVASION; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN FUNCTION; PROTEIN SYNTHESIS; TUMOR CELL LINE; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; DRUG COMBINATION; GENETICS; MALE; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

CELL DIVISION; COLLAGEN; DRUG COMBINATIONS; EPIDERMAL GROWTH FACTOR; HUMANS; LAMININ; MALE; NEOPLASM INVASIVENESS; PLASMINOGEN ACTIVATORS; PROSTATIC NEOPLASMS; PROTEOGLYCANS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 1242296018     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/jbm.2008.2852     Document Type: Article

References (35)

1. Peehl D, Wong S. In vitro studies of human prostatic epithelial cells: Attempts to identify distinguishing features of malignant cells. Growth Factors 1989; 1: 237-50.
2. Maddy SQ, Chisholm GD, Hawkins RA, Habib FK. Localization of epidermal growth factor receptors in the human prostate by biochemical and immunocytochemical methods. J Endocrinol 1986; 113: 147-53.
3. Carruba G, Leake RE, Rinaldi F, et al. Steroid-growth factor interaction in human prostate cancer. 1. Short term effects of transforming growth factors on growth of human prostate cancer cells. Steroids 1994; 59: 412-20.
4. Schuurmans ALG, Bolt J, Mulder E. Androgens and transforming growth factor α modulate the growth response to epidermal growth factor in human prostatic tumor cells (LNCaP). Mol Cell Endocrinol 1988; 60: 101-4.
5. Tu H, Jacobs SC, Borkowski A, Kyprianou N. Incidence of apoptosis and cell proliferation in prostate cancer: Relationship with TGF α1 and bcl-2 expression. Int J Cancer 1996; 69: 357-63.
6. Nicholson RI, McClelland RA, Finlay P, et al. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 1993; 29: 1018-23.
7. Leake R. The cell cycle and regulation of cancer cell growth. Ann N Y Acad Sci 1996; 784: 252-62.
8. MacDonald A, Chisholm GD, Habib FK. Production and response of a human prostatic cancer cell line to transforming growth factor-like molecules. Br J Cancer 1990; 62: 579-84.
9. Bishop JM. The molecular genetics of cancer. Science 1987; 235: 305-11.
10. Onda M, Matsuda S, Higaki S, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 1996; 77: 71-8.
11. Dinney CP, Parker C, Dong Z, et al. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide. Clin Can Res 1997; 3: 161-8.
12. Fox SB, Persad RA, Coleman N, Silcocks PB, Collins CC. Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic adenocarcinoma. Br J Urol 1994; 74: 214-20.
13. Ganesh S, Sier CF, Griffioen G, et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994; 48: 4065-71.
14. Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: From pilot to level 1 evidence studies. Clin Chem 2002; 48: 1194-7.
15. Pedersen H, Brunner N, Francis D, et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994; 54: 4671-5.
16. Billstrom A, Hartley-Asp B, Lecander I, Batra S, Astedt B. The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostate tumor in SCID mice. Int J Cancer 1995; 61: 542-7.
17. Schmitt M, Janicke F. Tumor-associated urokinase-type plasminogen activator: Biological and clinical significance. Biol Chem Hoppe-Seyler 1992; 373: 611-22.
18. Billstrom A, Lecander I, Dagnaes-Hansen F, Dahllof B, Stenram U, Hartley-Asp B. Differential expression of uPA in an aggressive (DU145) and a nonaggressive (1013L) human prostate xenograft. Prostate 1995; 26: 94-104.
19. Festuccia C, Vincentini C, Di Pasquale AB, et al. Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Oncology Res 1995; 7: 131-8.
20. Romain S, Chinot O, Klijn JGM, Van Putten WLJ, Martin PM, Foekens JA. Prognostic value of cytosolic tyrosine kinase activity in 249 node-positive breast cancer patients. Br J Cancer 1994; 70: 304-8.
21. Jeffers M, Rong S, Vande Woude GF. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biology 1996; 16: 1115-25.
22. Kaighn ME, Narayan SK, Ohnuki O, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC3). Invest Urol 1979; 17: 16-23.
23. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostatic carcinoma cell line (DU145). Int J Cancer 1978; 21: 274-81.
24. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-42.
25. de Witte JH, Sweep CG, Klijn JG, et al. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. Br J Cancer 1999; 79: 1190-8.
26. Gaylis FD, Keer HN, Wilson MJ, Kwaan HC, Sinha A, Kozlowski JM. Plasminogen activators in human prostate cancer cell lines and tumors: Correlation with the aggressive phenotype. J Urology 1989; 142: 193-8.
27. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987; 47: 3239-45.
28. Schlechte W, Brattain M, Boyd D. Invasion of extracellular matrix by cultured colon cancer cells: Dependence on urokinase receptor display. Cancer Comm 1990; 2: 173-9.
29. Hurley WL, Blatchford DR, Hendry KAK, Wilde CJ. Extracellular matrix and mouse mammary cell function: Comparison of substrate in culture. In Vitro Cell Dev Biol 1994; 30: 529-38.
30. Jones HE, Dutkowski CM, Barrow D, Harper ME, Wakeling AE, Nicholson RJ. New EGFR-selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC3 and DU145. Int J Cancer 1997; 71: 1010-8.
31. Simpson BJ, Bartlett JM, Macleod KG, et al. Inhibition of transforming growth factor alpha (TGF-alpha)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868. Br J Cancer 1999; 79: 1098-103.
32. Buchdunger E, Trinks U, Mett H, Regenass U, Muller M, Meyer T. 4,5-Dianilinophtalimide: A protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc Natl Acad Sci USA 1994; 91: 2334-8.
33. Kondapaka BS, Reddy KB. Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer. Mol Cell Endoc 1996; 117: 53-8.
34. Penar PL, Khoshoymn S, Bhushan A, Triton TR. Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgery 1997; 40: 141-51.
35. Harper ME, Goddard L, Glynne-Jones E, et al. Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor. Prostate 2002; 52: 59-68.